Opus Genetics (NASDAQ:IRD – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Volatility and Risk
Opus Genetics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Profitability
This table compares Opus Genetics and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -1,091.82% | N/A | -150.13% |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
Analyst Recommendations
This is a summary of current recommendations for Opus Genetics and Cardiff Oncology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 1 | 1 | 16 | 1 | 2.89 |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
Opus Genetics presently has a consensus price target of $12.71, indicating a potential upside of 209.35%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 698.72%. Given Cardiff Oncology’s higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Opus Genetics.
Institutional & Insider Ownership
15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Opus Genetics and Cardiff Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 23.92 | -$49.59 million | ($1.35) | -3.04 |
| Cardiff Oncology | $590,000.00 | 123.80 | -$45.85 million | ($0.60) | -1.56 |
Cardiff Oncology has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
